Cadence Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cadence Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-33,981	Closed	-$1.89M	–	420
2020 Q2	$1.89M	Buy	33,981 +43	+0.1%	+$1.84K	0.27%	84
2020 Q1	$1M	Sell	33,938 -877	-3%	-$29.7K	0.17%	186
2019 Q4	$1.26M	Sell	34,815 -705	-2%	-$21.6K	0.14%	218
2019 Q3	$967K	Buy	+35,520	New	+$918K	0.14%	267
2014 Q3	–	Sell	-292,090	Closed	-$4.62M	–	615
2014 Q2	$4.62M	Sell	292,090 -91,700	-24%	-$1.31M	0.22%	155
2014 Q1	$5.8M	Buy	+383,790	New	+$4.33M	0.24%	163

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Cadence Capital Management's HZNP Position: Q3 2020 in Review

Cadence Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2020, closing a stake of 33,981 shares — an estimated $1.89M sold.

Cadence Capital Management first reported a position in HZNP in Q1 2014 and held it in 6 quarters. The position peaked at $5.8M in Q1 2014. 433 funds tracked by Wall St. Rank hold HZNP as of Q3 2020.

Cadence Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2020 after selling out during the quarter.
Cadence Capital Management sold 33,981 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2020, an estimated $1.89M.
Cadence Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 6 quarters.
Cadence Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.8M in Q1 2014.
433 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.